Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN vs ACULAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin and thromboxane synthesis, which leads to analgesic, antipyretic, and anti-inflammatory effects.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.
Migraine pain relief,Headache,Muscle aches,Menstrual cramps,Arthritis,Reduction of risk of myocardial infarction (low-dose)
Treatment of postoperative inflammation in patients who have undergone cataract extraction,Relief of ocular itching due to seasonal allergic conjunctivitis
500-1000 mg orally every 4-6 hours as needed; maximum 4000 mg in 24 hours.
One drop of 0.5% ophthalmic solution into the affected eye(s) four times daily.
Aspirin half-life is 15-20 minutes due to rapid hydrolysis to salicylate. Salicylate terminal half-life is 2-3 hours at low doses, up to 15-30 hours at high doses or with toxicity. At analgesic doses (600-1000 mg), effective half-life is ~3-4 hours, requiring q4-6h dosing.
Terminal half-life: 1.8 hours (ketorolac tromethamine); clinical context: short half-life supports dosing every 6 hours for acute pain, but prolonged in elderly or renal impairment (↑ to 5-6 hours, thus dose reduction required).
Primarily metabolized by hepatic esterases to salicylate; conjugation with glycine (salicyluric acid) and glucuronic acid (salicyl phenolic glucuronide) mainly in the liver; also metabolized by cytochrome P450 (CYP) enzymes (CYP2C9) to a lesser extent.
Hepatic metabolism primarily via cytochrome P450 2C9 (CYP2C9).
Renal excretion of salicylate and its metabolites (salicyluric acid, salicyl phenolic glucuronide, salicyl acyl glucuronide, gentisic acid). Approximately 90% of a dose is excreted renally; 10% via bile/feces. Excretion is dose- and p H-dependent: alkaline urine increases clearance.
Renal: ~80% as unchanged drug and glucuronide conjugates; biliary/fecal: ~20%
80-90% bound to serum albumin, primarily binding site I (warfarin site). Binding is saturable and decreases at high concentrations, increasing free fraction and toxicity risk.
99% bound; primary binding protein: albumin.
0.15-0.2 L/kg for aspirin; for salicylate 0.1-0.2 L/kg. Low Vd reflects limited extravascular distribution; does not extensively penetrate brain except at high doses (therapeutic for migraine likely CNS penetration via passive diffusion).
0.11-0.25 L/kg; clinical meaning: low Vd indicates primarily confined to extracellular compartment (plasma and interstitial fluid), minimal tissue penetration.
Oral immediate-release aspirin: 50-75% (due to first-pass hydrolysis in GI mucosa and liver). Enteric-coated: reduced and delayed absorption. Rectal: 20-50% (variable). For BAYER EXTRA STRENGTH ASPIRIN (500 mg), ~60% bioavailability.
Ophthalmic: ~2% systemic absorption after topical instillation (due to corneal permeability and nasolacrimal drainage); oral formulation not used for Acular (ophthalmic only).
GFR 10-50 m L/min: avoid or reduce dose to 500 mg every 6 hours; GFR <10 m L/min: contraindicated.
No dosage adjustment required for renal impairment.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% or extend interval to 8 hours; Class C: contraindicated.
No dosage adjustment required for hepatic impairment.
Weight <40 kg: 10-15 mg/kg orally every 4-6 hours, maximum 60 mg/kg/day; Weight ≥40 kg: adult dosing.
Safety and efficacy in pediatric patients have not been established; use not recommended.
Start at lowest effective dose (500 mg every 6-8 hours); monitor renal function and bleeding risk.
No specific dosage adjustment required; use same dosing as for younger adults.
Reye's syndrome: Aspirin should not be used in children or teenagers with viral infections due to risk of Reye's syndrome.
No FDA boxed warning.
Increased risk of gastrointestinal bleeding, ulcers, and perforation; hypersensitivity reactions including anaphylaxis; increased bleeding risk; severe hepatic injury; caution in patients with asthma, G6PD deficiency, renal impairment, or history of peptic ulcer disease.
May increase bleeding time due to inhibition of platelet aggregation; use with caution in patients with known bleeding tendencies or those receiving other medications that may prolong bleeding time.,May cause corneal effects including keratitis and corneal thinning; discontinue if corneal epithelial breakdown occurs.,Use with caution in patients with prior sensitivity to aspirin, phenylacetic acid derivatives, or other NSAIDs.,May delay wound healing or exacerbate infections; avoid use in patients with active epithelial herpes simplex keratitis.
Hypersensitivity to aspirin or NSAIDs; active peptic ulcer disease; severe hepatic or renal impairment; bleeding disorders; patients with viral infections (children/teenagers) due to Reye's syndrome risk; third trimester of pregnancy.
Hypersensitivity to ketorolac tromethamine or any component of the formulation,History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,Active epithelial herpes simplex keratitis,Late pregnancy (third trimester) due to risk of premature closure of ductus arteriosus
High-fat meals may delay absorption and reduce efficacy. Avoid alcohol to minimize GI bleeding risk. No significant food interactions beyond general GI irritation, but taking with food may improve tolerance.
No known food interactions. Avoid alcohol if concomitant oral NSAIDs are used due to increased risk of gastrointestinal bleeding, but this is not specific to ophthalmic use.
First trimester: Epidemiologic studies suggest an increased risk of gastroschisis and possibly other congenital anomalies with use, though absolute risk is low. Second trimester: Avoid due to potential effects on fetal renal function and premature closure of ductus arteriosus, though risk is lower than third trimester. Third trimester: Contraindicated. Use in third trimester increases risk of premature closure of ductus arteriosus, oligohydramnios, and periventricular hemorrhage in the fetus; may prolong gestation and labor.
Pregnancy Category C. No adequate studies in pregnant women. Ketorolac tromethamine, like other NSAIDs, may cause premature closure of the ductus arteriosus and fetal renal impairment in the third trimester. First and second trimester use should be avoided unless clearly needed. The potential benefits should be weighed against the risks.
Aspirin (acetylsalicylic acid) is excreted into breast milk in low concentrations. Milk-to-plasma ratio (M/P) is approximately 0.03-0.11 for salicylate. No adverse effects in breastfeeding infants have been reported with occasional low doses. However, regular high-dose use may lead to accumulation and potential toxicity in the infant (e.g., Reye's syndrome). Avoid use during breastfeeding; if needed, use lowest effective dose and monitor infant for bruising, bleeding, or metabolic acidosis.
Ketorolac is excreted in human milk at low levels. The M/P ratio is not well defined. Due to potential adverse effects in nursing infants, caution is advised. Use only if clearly indicated and consider alternative agents.
Aspirin pharmacokinetics in pregnancy: Increased renal clearance and plasma volume may lower salicylate concentrations. However, due to teratogenic risks, routine aspirin use is not recommended. For specific indications (e.g., preeclampsia prevention, antiphospholipid syndrome), low-dose aspirin (81 mg/day) is used without dose adjustment. For high-dose or anti-inflammatory doses (e.g., 650 mg every 4-6 hours), avoid entirely in pregnancy, especially in third trimester.
No specific dose adjustments are recommended for pregnancy; however, use the lowest effective dose for the shortest duration due to potential fetal risks. Physiological changes in pregnancy (increased volume of distribution, renal clearance) may alter pharmacokinetics, but no formal studies justify dose modification.
For migraine pain, aspirin 500-1000 mg (equivalent to 2-4 tablets of Bayer Extra Strength) is recommended at onset. Note that aspirin is contraindicated in patients with a history of nasal polyps, angioedema, or bronchospasm with NSAIDs. Monitor for tinnitus or hearing loss as signs of salicylate toxicity. Avoid use within 48 hours of alcohol cessation therapy due to GI irritation.
ACULAR (ketorolac tromethamine ophthalmic solution) is a nonsteroidal anti-inflammatory drug (NSAID) used for ocular inflammation. Avoid concomitant use with other NSAIDs or corticosteroids due to increased risk of corneal adverse events. Use with caution in patients with bleeding disorders or those on anticoagulants, as it may increase bleeding tendency. Monitor for corneal toxicity, especially in patients with compromised corneal integrity. Ensure proper storage at room temperature and discard if solution changes color or becomes cloudy.
Take this medication at the first sign of migraine pain for best results.,Do not exceed 8 tablets (4000 mg aspirin) in 24 hours.,Avoid alcohol while taking aspirin to reduce risk of stomach bleeding.,Do not use if you have a history of stomach ulcers, bleeding disorders, or asthma triggered by aspirin.,Consult a doctor if your migraine does not improve after 1-2 doses or if you have severe symptoms.,Keep out of reach of children; Reye's syndrome warning if given to children or teenagers with viral illness.
Do not touch the dropper tip to any surface to avoid contamination.,Remove contact lenses before instillation and wait at least 15 minutes before reinserting.,Apply pressure to the inner corner of the eye (nasolacrimal occlusion) for 1 minute after instillation to reduce systemic absorption.,Do not use while wearing soft contact lenses, as the preservative may be absorbed.,Report any signs of corneal problems such as pain, redness, or vision changes immediately.,Use exactly as prescribed and do not share the medication with others.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN vs ACULAR, answered by our medical review team.
BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN is a NSAID / Antiplatelet that works by Irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin and thromboxane synthesis, which leads to analgesic, antipyretic, and anti-inflammatory effects.. ACULAR is a NSAID Ophthalmic that works by Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN and ACULAR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN is: 500-1000 mg orally every 4-6 hours as needed; maximum 4000 mg in 24 hours.. The standard adult dose of ACULAR is: One drop of 0.5% ophthalmic solution into the affected eye(s) four times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN and ACULAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN is classified as Category D/X. First trimester: Epidemiologic studies suggest an increased risk of gastroschisis and possibly other congenital anomalies with use, though absolute risk is low. Second trimester: A. ACULAR is classified as Category C. Pregnancy Category C. No adequate studies in pregnant women. Ketorolac tromethamine, like other NSAIDs, may cause premature closure of the ductus arteriosus and fetal renal impairm. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.